<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326273</url>
  </required_header>
  <id_info>
    <org_study_id>JROHH0202</org_study_id>
    <nct_id>NCT01326273</nct_id>
  </id_info>
  <brief_title>Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation</brief_title>
  <official_title>Adoptive Transfer of Autologous CMV Specific CD8+ T Cells After Allogeneic Stem Cell Transplantationas Treatment for CMV Reactivation: A Phase I/II Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will assess whether the infusion of autologous CMV-specific T-cells at the&#xD;
      time of CMV reactivation posttransplant will prevent worsening of CMV virus reactivation&#xD;
      posttransplant to a level that warrants therapy with antiviral drugs (objectively assessed by&#xD;
      looking at CMV virus copy number).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic Hematopoietic Stem Cell transplantation (allo-SCT) remains the only curative&#xD;
      approach for a number of patients with hematological malignancies. However, the use of&#xD;
      allo-SCT can expose patients to prolonged periods of immunosupression during which time viral&#xD;
      infections can be a significant cause of morbidity and mortality.&#xD;
&#xD;
      Human cytomegalovirus (CMV) infection and reactivation still represents one of the most&#xD;
      important and lifethreatening complications in immunocompromised patients. Prophylaxis or&#xD;
      early treatment with antiviral drugs after CMV reactivation have reduced the mortality&#xD;
      related to this complication. However, the antiviral drugs have many side-effects and are&#xD;
      costly. Furthermore, CMV infection refractory to antiviral treatment after alloSCT is&#xD;
      associated with a high mortality. A number of studies have shown the efficacy of selecting&#xD;
      Tcells against the virus from the donor and infusing them into the recipient (adoptive&#xD;
      transfer of immunity) to prevent or treat CMV reactivation. However this approach relies on&#xD;
      the donor having preexisitng immunity to CMV (50% of the healthy population is CMV&#xD;
      seronegative and therefore have no preexisting immunity against CMV). We propose an&#xD;
      alternative approach to collect CMV specific Tcells from the seropositive recipient prior to&#xD;
      transplantation; the autologous CMV specific T cells will then be infused back into the&#xD;
      recipient at the time of CMV reactivation post-transplant.&#xD;
&#xD;
      This approach is especially relevant where the donor is CMV seronegative or unavailable or&#xD;
      following the use of cord blood transplant where there is no memory T cell response to CMV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to adoptive transfer of autologous CMV-specific CD8+ T-cells</measure>
    <time_frame>Up to three years</time_frame>
    <description>Response to CMV-specific CD8+ T-cells administration will be measured and defined as a CMV DNA PCR&lt; 50 copies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The occurrence of subsequent CMV reactivations</measure>
    <time_frame>Up to three years</time_frame>
    <description>The occurrence of subsequent CMV reactivations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete response</measure>
    <time_frame>Up to three years</time_frame>
    <description>The rate of complete response will be analyzed and compared to patients treated with anti-viral drugs only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of early complete response</measure>
    <time_frame>Up to three years</time_frame>
    <description>The rate of early complete response will be analyzed and compared to patients treated with anti-viral drugs only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of subsequent CMV reactivation</measure>
    <time_frame>Up to three years</time_frame>
    <description>The rate of subsequent CMV reactivation will be analyzed and compared to patients treated with anti-viral drugs only.</description>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>CMV Reactivation</condition>
  <condition>Allogeneic Stem Cell Transplantation</condition>
  <condition>Autologous CMV Specific CD8+ T Cells</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lymphopheresis</intervention_name>
    <description>Lymphopheresis</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CMV specific lymphocyte infusion</intervention_name>
    <description>CMV specific lymphocyte infusion</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral blood for CMV DNA PCR</intervention_name>
    <description>Peripheral blood for CMV DNA PCR</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Haematology/Blood chemistry</intervention_name>
    <description>Haematology/Blood chemistry analysis, Collection of blood for ancillary laboratory tests.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have received an allogeneic stem cell transplant from any donor, as&#xD;
             treatment for a haematological malignancy.&#xD;
&#xD;
          2. HLAA0201 positive at one allele&#xD;
&#xD;
          3. CMV seropositive&#xD;
&#xD;
          4. The patient must be willing and capable of donating lymphocytes for CMVspecific CD8+ T&#xD;
             cell selection using apheresis techniques&#xD;
&#xD;
          5. The patient must be in complete remission with no evidence of circulating blasts or&#xD;
             other malignant cells&#xD;
&#xD;
          6. Patient must be fit to undergo leukapheresis&#xD;
&#xD;
          7. Patients must have signed an informed consent form before undergoing LP prior to&#xD;
             alloSCT&#xD;
&#xD;
        Indications for infusion of autologous CMV specific CD8+ Tcells:&#xD;
&#xD;
          -  Therapeutic: CMV disease following allogeneic stem cell transplantation&#xD;
&#xD;
          -  Preemptive: CMV reactivation (by CMV DNA PCR)&#xD;
&#xD;
          -  autologous CMV specific CD8+ T-cells must be infused into the patient no later than 72&#xD;
             following CMV reactivation.&#xD;
&#xD;
          -  Steroids should be withdrawn at least 1 week before the infusion of CMVspecific CD8+&#xD;
             T-cell&#xD;
&#xD;
          -  Patients must have signed an informed consent form before the infusion of autologous&#xD;
             CMV specific CD8+ T-cells&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient CMV seronegative&#xD;
&#xD;
          2. No informed consent&#xD;
&#xD;
          3. Patient positive at the time of LP for one of the following infectious agents: HIV,&#xD;
             HBV, HCV,Syphilis, HTLV 1 and 2&#xD;
&#xD;
          4. Patient with circulating leukemic blasts at the time of LP&#xD;
&#xD;
        Exclusion criteria for infusion of autologous CMV specific CD8+ T cells:&#xD;
&#xD;
        Severe GvHD (grade IIII-V) requiring full dose immunosuppressive treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katy Rezvani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College Healthcare NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>March 22, 2011</study_first_submitted>
  <study_first_submitted_qc>March 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2011</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CMV</keyword>
  <keyword>cytomegalovirus</keyword>
  <keyword>autologous</keyword>
  <keyword>leukemia</keyword>
  <keyword>hematological malignancies</keyword>
  <keyword>stem cell transplantation</keyword>
  <keyword>CMV reactivation</keyword>
  <keyword>adoptive therapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

